The average one-year price target for Greenwich LifeSciences (NasdaqCM:GLSI) has been raised to $48.45 per share, representing a 13.10% increase from the previous estimate of $42.84 dated December 18, 2025. This new target suggests a potential upside of 66.95% from the most recent closing price of $29.02 per share. Analyst targets range from $45.45 to $52.50.
As of the last quarter, 116 funds reported positions in Greenwich LifeSciences, a decrease of 5 funds (4.13%). Institutional ownership fell 6.56% to 1,502K shares, with average portfolio weight dedicated to GLSI increasing slightly to 0.00%. Among notable shareholders, iShares Russell 2000 ETF increased its stake by 7.05% to 157K shares, while Northern Trust decreased its holdings by 9.06% to 76K shares.
